| 3.22 0.14 (4.55%) | 03-10 11:17 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.27 |
1-year : | 4.99 |
| Resists | First : | 3.66 |
Second : | 4.27 |
| Pivot price | 3.26 |
|||
| Supports | First : | 3.17 |
Second : | 2.87 |
| MAs | MA(5) : | 3.22 |
MA(20) : | 3.26  |
| MA(100) : | 4.9 |
MA(250) : | 3.52 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 38.5 |
D(3) : | 42.9 |
| RSI | RSI(14): 46.5 |
|||
| 52-week | High : | 12.14 | Low : | 1.2 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ EVAX ] has closed below upper band by 44.1%. Bollinger Bands are 78.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 18 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.28 - 3.3 | 3.3 - 3.32 |
| Low: | 3.03 - 3.05 | 3.05 - 3.07 |
| Close: | 3.04 - 3.08 | 3.08 - 3.11 |
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
Wed, 15 Oct 2025
Evaxion shares spike as AI-designed melanoma vaccine data hits market - Mugglehead Investment Magazine
Thu, 25 Sep 2025
$592M Potential Deal: Evaxion's AI-Powered Vaccine Platform Lands Major MSD Partnership for Novel Pathogen - Stock Titan
Thu, 25 Sep 2025
Evaxion Stock Climbs Amid Biotech Surge - StocksToTrade
Mon, 26 May 2025
Evaxion: Progress Unrecognized By Market And A Catalyst-Full 2025 (NASDAQ:EVAX) - Seeking Alpha
Fri, 31 Jan 2025
Evaxion Biotech A/S Closes Public Offering Raising $10.8 Million to Advance AI-Powered Vaccine Pipeline - Nasdaq
Fri, 10 Jan 2025
Evaxion Biotech A/S Announces Revised Effective Date for Change in American Depositary Shares Ratio - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 8 (M) |
| Shares Float | 449 (M) |
| Held by Insiders | 18.3 (%) |
| Held by Institutions | 7.8 (%) |
| Shares Short | 82 (K) |
| Shares Short P.Month | 105 (K) |
| EPS | -4 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.26 |
| Profit Margin | -102.4 % |
| Operating Margin | -122.7 % |
| Return on Assets (ttm) | -28.3 % |
| Return on Equity (ttm) | -100.2 % |
| Qtrly Rev. Growth | -100 % |
| Gross Profit (p.s.) | 0.9 |
| Sales Per Share | 0.9 |
| EBITDA (p.s.) | -1.04 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -0.83 |
| PEG Ratio | 0 |
| Price to Book value | 2.59 |
| Price to Sales | 3.64 |
| Price to Cash Flow | -4.15 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|